Journal list Promote Sponsor
verified SJR 1,15 · Q1 • database Scopus / SJR & Web of Science indexed
Expert Opinion on Biological Therapy
United Kingdom · Taylor and Francis Ltd.
workspace_premium Q1 — Drug Discovery lock Subscription

Expert Opinion on Biological Therapy

Expert Opinion on Biological Therapy is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 107. It has a price of 4000 €. It has an SJR impact factor of 1,15 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,15.

Expert Opinion on Biological Therapy focuses its scope in these topics and keywords: therapy, treatment, cancer, vaccine, multiple, cell, conjugate, myelomarecent, myeloid, children, ...

ISSN: 1471-2598
Publisher: Taylor and Francis Ltd.
Category: Drug Discovery
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
1,15 Q1
H-index 107
Acceptance rate pie_chart
25% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
4.000 € Subscription
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,15

H-index

107

Docs (year)

133

Docs 3y

418

Total refs

9290

Cites 3y

1594

Citable 3y

364

Cites/Doc 2y

3.55

Ref/Doc

69.85

Immediate OA

4000 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Cambridge Healthtech Institute?s 5th Annual ?Molecular Display: The Chemistry Set for Proteins and Small Molecules? Conference

View more

Yersinia pestis (plague) vaccines

View more

Developments in the area of bioadhesive drug delivery systems

View more

Development of immunotherapeutic strategies for HIV-1

View more

Development of 2A peptide-based strategies in the design of multicistronic vectors

View more

Dendritic cell maturation in active immunotherapy strategies

View more

Delivery of novel macromolecular drugs against HIV-1

View more

Defensive applications of gene transfer technology in the face of bioterrorism: DNA-based vaccines and immune targeting

View more

DAB389IL2 (ONTAK') fusion protein therapy of chronic lymphocytic leukaemia

View more

Current status of adoptive immunotherapy of malignancies

View more

Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications

View more

Chemical and biological properties of polymer-modified proteins

View more
SHOW MORE ARTICLES

Cell-based therapy approaches using dying cells: from tumour immunotherapy to transplantation tolerance induction

View more

90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma

View more

Brentuximab vedotin in systemic T-cell lymphoma

View more

Bone tissue engineering: recent advances and promising therapeutic agents

View more

Bioluminescence imaging in vivo application to cancer research

View more

Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?

View more

Biological therapy in hereditary angioedema: transformation of a rare disease

View more

Bacterial spores as heat stable vaccine vehicles

View more

B7-H1-targeted immunotherapy for head and neck cancer

View more

Autologous activated platelet-rich plasma (AA-PRP) and non-activated (A-PRP) in hair growth: a retrospective, blinded, randomized evaluation in androgenetic alopecia

View more

Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA

View more

Angiogenesis, views and news. The 93rd Annual Meeting of the American Association for Cancer Research

View more

FAQs